We combine deep disease expertise and multiple drug modalities with a goal of reducing risk and speeding time for treatments to reach patients. Our portfolio is grounded in a long history of research into small molecules. We have a unique approach in developing novel biological medicines, and groundbreaking research capabilities in cell therapy.
We believe in the power of partnerships.
Our ambition is to be a trusted partner to the patient community. We are committed to collaborating with patients across the lifecycle of medicines.
We apply and invest our breadth of resources in new technologies and programs with the potential and goal to radically improve treatment paradigms.
Our purpose is to create impact together with patients worldwide. By 2028, we aim to add more years of life and quality of life for patients. We aim to develop pivotal stage therapies for patients, with patients and the healthcare community. We aim to be a diverse, equitable, inclusive, and trusted organization. Plus, we aim to be climate neutral, and to provide access to our medicines across all contintents.
The UK and Ireland operation of Galapagos was set up in 2020, aiming to offer patients in the UK and Ireland with treatment options for unmet medical needs in therapeutic areas like immunology. At Galapagos, we are proud to be among a rare group of fully integrated biotech companies advancing early research to be a marketed medicine. Today we are building on our foundation and continually adding to our pipeline of innovations. Through ongoing development and through discovery and acquisition, we aim to make a positive impact on patients living with life changing diseases.
GB--FIL-202308-00005 | Date of preparation: October 2023